The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Open accessAbstract
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was demonstrated using…”
BackgroundSelf-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationLong-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619
Self-citationMarks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
Self-citationRequirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337
Cited by
Sorted by citations
Items 601–700 of 813
Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom
Ibrahim, H., Chean, C. S., Kalakonda, A. J. M., Kwan, J., Kumar, P., Williams, S., & Beare, N. A. V. (2024) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2024.2396007 · Cited by 4
Reprint of: B Cells in Chronic Graft-versus-Host Disease
Sarantopoulos, S., Blazar, B. R., Cutler, C. S., & Ritz, J. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.033 · Cited by 4
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia
Tripathi, R., Lee‐Vergés, E., Higashi, M., Giménez, N., Rosich, L., López‐Guerra, M., & Colomer, D. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1362387 · Cited by 4
Next-Generation Bruton Tyrosine Kinase Inhibitors
Stephens, D. M., & Byrd, J. C. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01594 · Cited by 4
Self-citationMudasani, G., Paidikondala, K., Gurská, S., Maddirala, S. J., Džubák, P., Das, V., & Gundla, R. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100699 · Cited by 4
Walker, C., Horowitz, A., Nooruddin, Z. I., & Frei, C. R. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231181113 · Cited by 4
Forrester, J. D., Gómez, C. A., Forrester, J. A., Nguyen, M., Gregg, D. L., Deresinski, S. C., Banaei, N., & Weiser, T. G. (2015) · Mycoses · doi:10.1111/myc.12364 · Cited by 4
Parikh, M., Tenold, M. E., Qi, L., Lara, F., Robles, D., Meyers, F. J., & Lara, P. N. (2021) · Kidney Cancer · doi:10.3233/kca-210128 · Cited by 4
Yu, H., Mi, L., Zhang, W., Ye, Y., Li, M., Hu, D., Cao, J., Wang, D., Wang, X., Ding, N., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3056 · Cited by 4
New drugs for the treatment of non-Hodgkin lymphomas.
Smith, S. M. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.03.01 · Cited by 4
CLL: an acquired immunodeficiency disease
Zent, C. S. (2016) · Blood · doi:10.1182/blood-2016-08-734475 · Cited by 4
Development and Significance of Mouse Models in Lymphoma Research
Noble, J. N., & Mishra, A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00504-0 · Cited by 4
Self-citationIbrutinib for the treatment of chronic lymphocytic leukemia
Deodato, M., Frustaci, A. M., Zamprogna, G., Cairoli, R., Montillo, M., & Tedeschi, A. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1597703 · Cited by 4
Zhong, L. X., Lu, A., Lu, X., Liu, X., Cao, L., Zhu, S., Diao, S., Cheng, X., Wu, H., & Chen, J. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251319394 · Cited by 3
Andreadis, C. B., Bobek, O. J., Hsi, E. D., Fenske, T. S., Stiff, P. J., Hill, B. T., Geyer, S. M., Horwitz, M. E., Khimani, F., Little, R. F., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2525982 · Cited by 3
Ophthalmic Adverse Events of Systemic Immunotherapy and Targeted Cancer Therapy: A Review
Dong, M. R., Chiu, Z. K., Lim, L. L., & Lin, M. L. (2026) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70059 · Cited by 3
Guo, Z., Ye, F., Zhang, Y., Xu, D., Shi, X., Wang, C., & Zhu, J. (2025) · Immunology · doi:10.1111/imm.70003 · Cited by 3
Bevilacqua, A., Cellini, A., Angotzi, F., Serafin, A., Mazzetto, F., Danesin, N., Piazza, F., Trentin, L., & Visentin, A. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2523552 · Cited by 4
Responses and response evaluation of immune checkpoint inhibitors in lymphoma
Anagnostou, T., & Ansell, S. M. (2017) · Annals of Lymphoma · doi:10.21037/aol.2017.10.03 · Cited by 3
The Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitro
Mert, U., Müftüoğlu, C., ERDEM, S., Sadıqova, A., Töz, S. O., Özbel, Y., & Caner, A. (2022) · Acta Parasitologica · doi:10.1007/s11686-022-00630-5 · Cited by 3
Tazoe, K., Nishimoto, M., Yamamoto, A., Makuuchi, Y., Kuno, M., Okamura, H., Nakashima, Y., Tanaka, S., Ohsawa, M., Hino, M., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1139-22 · Cited by 3
Mihăilă, R. G. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.241 · Cited by 3
Pierre, C. S., Guo, J., Shin, J. D., Engstrom, L., Lee, H., Herbert, A. G., Surdi, L. M., Baker, J. Α., Salmon, M., Shah, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180870 · Cited by 3
Long, M. (2018) · Blood · doi:10.1182/blood-2018-10-876078 · Cited by 3
Ringelstein‐Harlev, S. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1755857 · Cited by 3
An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia
Lim, K. J. C., & Tam, C. S. L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1770727 · Cited by 3
Popov, V. M., Matei, C. O., Omer, M., Onisâi, M., Matei, M. B., Savopol, T., Bumbea, H., & Moisescu, M. G. (2020) · Europe PMC (PubMed Central) · Cited by 3
SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation
Romano, I. J., Condoluci, A., & Rossi, D. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.08.002 · Cited by 3
Mohty, R., Alotaibi, S., Gadd, M. E., Luo, Y., Parrondo, R. D., Qin, H., & Kharfan‐Dabaja, M. A. (2023) · Clinical Hematology International · doi:10.46989/001c.88382 · Cited by 3
Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma
Jahangiri, S., Friedberg, J. W., & Barr, P. M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.929663 · Cited by 3
Chan, K. L., Lokan, J., Tam, C. S. L., Lew, T. E., & Prince, H. M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1179298 · Cited by 3
No longer too exhausted to run
Gribben, J. G. (2018) · Blood · doi:10.1182/blood-2018-06-851642 · Cited by 3
Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report
Dai, X., Tian, F., Xu, Z., Kong, X.-T., Jiang, P., Xia, W., & Zhu, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-469 · Cited by 3
Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib
Marcaillou, M., Delaumenie, S., Bourgaux, M., Sénéschal, J., & Bédane, C. (2020) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001745 · Cited by 3
Kondo, T., Ikegawa, S., Fukumi, T., Sumii, Y., Sugiura, H., Sando, Y., Nakamura, M., Meguri, Y., Iwamoto, M., Maeda, Y., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100042 · Cited by 3
Danilov, A. V. (2015) · British Journal of Haematology · doi:10.1111/bjh.13601 · Cited by 3
Does BTKi improve CAR T-cell therapy in MCL?
Boardman, A. P., & Palomba, M. L. (2024) · Blood · doi:10.1182/blood.2023022898 · Cited by 3
Liu, C., Lin, F.-J., Chhay, C., Chen, Y., Lin, Y.-K., Lin, Y., Chan, C., Higa, S., Chen, S.-A., & Chen, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176675 · Cited by 2
Silva-Carvalho, A. É., Bispo, E. C. I., da Silva, I. G. M., Corrêa, J. R., Carvalho, J. L., Gelfuso, G. M., & Saldanha‐Araújo, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71054-6 · Cited by 2
New treatment strategies for primary central nervous system lymphoma
Gilbert, A., Houillier, C., & Soussain, C. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001165 · Cited by 2
Three’s company: The cooperative signals behind the differentiation of Th9 cells
Rodriguez, J. A., Habib, H., & Olson, M. R. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101999 · Cited by 2
B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma
Quaglia, F. M., Gambino, S., Galasso, M., Vegliante, M. C., Visco, C., & Scupoli, M. T. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02468-6 · Cited by 2
Mejía, J. A. G., Duran, C., Zuluaga, M. L., Gómez-Durán, C. A., & Morales, M. S. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2603497 · Cited by 2
He, L., Liu, Y., Zhou, J., Zhang, T., Zhang, S., Ge, J., & Hong, J. (2026) · Cellular Immunology · doi:10.1016/j.cellimm.2026.105065 · Cited by 2
Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity
Lin, J.-R., Song, Y., Chou, Y., Chen, Y.-J., Hsiao, C., Li, J., Ho, Y., Liao, W.-C., Yen, H., & Liu, C.-H. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04335-w · Cited by 2
Myeloid CD93 binds to CD69 on T cells to drive resistance to T-cell engager therapy
Yu, H., Qian, Y., Huang, Y., Peng, R., Zou, M., Liu, D., Yang, T., Liu, W., Zhang, W., Cao, J., et al. (2026) · Vita · doi:10.15302/vita.2026.08.0064 · Cited by 2
Ibrutinib for the treatment of chronic lymphocytic leukemia
Farooqui, M. Z. H., & Wiestner, A. U. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.850413 · Cited by 2
Une spondylodiscite à Aspergillus chez un patient traité par ibrutinib
Petitdemange, A., Martin, A., Ruch, Y., Chatron, E., Karol, A., & Hansmann, Y. (2019) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2019.10.007 · Cited by 2
Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746
Akintola, O. A., Patterson, M. B., Smith, J. G., Demartino, G., Mitra, A., & Kisselev, A. F. (2024) · iScience · doi:10.1016/j.isci.2024.110961 · Cited by 2
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
Kačar, M., Al‐Hakim, A., & Savic, S. (2024) · BioDrugs · doi:10.1007/s40259-024-00696-9 · Cited by 2
Bruno, C., Whitcomb, A., Pincock, B., Aleman, I. D., Neves, J. H., Shaw, M., & Gonda, A. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0101 · Cited by 2
Yang, B., Yang, S., Wang, C., & Yu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1663522 · Cited by 2
Kleine Moleküle, ganz groß: niedermolekulare immunonkologische Kombinationstherapien
Huck, B. R., Kötzner, L., & Urbahns, K. (2017) · Angewandte Chemie · doi:10.1002/ange.201707816 · Cited by 2
Yang, S., Huang, X., & Gale, R. P. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100884 · Cited by 2
Sawalha, Y., & Advani, A. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00009-3 · Cited by 2
Matera, M. G., Rogliani, P., Bianco, A., & Cazzola, M. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020621 · Cited by 2
Oh, D., Alsina, M., Quinn, D. I., O'Dwyer, P. J., Chau, I., Kim, S. Y., Durán, I., Castellano, D., Berlin, J. D., Mellado, B., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11539-1 · Cited by 2
Nishikubo, M., Matsuo, H., Manabe, S., Ota, K., Ishii, J., Hiramoto, N., Hara, S., Kondo, T., & Ishikawa, T. (2024) · British Journal of Haematology · doi:10.1111/bjh.19504 · Cited by 2
Zhou, J., Ma, W., Hu, N., Ma, Y., Zhu, H., & Gao, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1467891 · Cited by 2
Mudasani, G., Rampeesa, N. K., Anugu, S. R., Muddasani, P., Gurská, S., Džubák, P., Hajdúch, M., Das, V., & Gundla, R. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118116 · Cited by 2
Frustaci, A. M., Montillo, M., Picardi, P., Mazzucchelli, M., Cairoli, R., & Tedeschi, A. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1191943 · Cited by 2
England, J. T., & Leitch, H. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1349904 · Cited by 2
Molecular Medicines for Parasitic Diseases
Singh, B. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91956 · Cited by 2
Hemorrhagic Cellulitis and Osteomyelitis Secondary to Ibrutinib Therapy
Tambe, A., Syed, W., Naqvi, M., Tambe, V., & Mandru, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000979 · Cited by 2
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia
Zent, C. S. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1589 · Cited by 2
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
Mar, N., Zakharia, Y., Falcón, A., Morales‐Barrera, R., Mellado, B., Durán, I., Oh, D., Williamson, S. K., Gajate, P., Arkenau, H., et al. (2023) · Cancers · doi:10.3390/cancers15112978 · Cited by 2
Yoon, Y., Park, H. Y., Chae, M. K., Jang, S. Y., & Yoon, J. S. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0729 · Cited by 2
Pitfalls of Combining Novel Agents in Lymphoma
Rodgers, T. D., & Barr, P. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0548-7 · Cited by 2
Ibrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia
Frustaci, A. M., Tedeschi, A., Deodato, M., Mazzucchelli, M., Cairoli, R., & Montillo, M. (2017) · Future Oncology · doi:10.2217/fon-2017-0466 · Cited by 2
Current Knowledge and Perspectives
Stickle, M., & Arnd‐Caddigan, M. (2019) · Routledge eBooks · doi:10.4324/9780429435522-2 · Cited by 2
Innocenti, I., Sorà, F., Autore, F., Chiusolo, P., Giammarco, S., Metafuni, E., Bacigalupo, A. P., Sica, S., & Laurenti, L. (2020) · Hematological Oncology · doi:10.1002/hon.2826 · Cited by 2
Khan, S., Durairaj, S., Phumphukhieo, P., Holding, S., & Allsup, D. J. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1885662 · Cited by 2
Novel immunotherapy in follicular lymphoma: a narrative review
Khurana, A., & Ansell, S. M. (2021) · Annals of Lymphoma · doi:10.21037/aol-20-48 · Cited by 2
New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
Iqbal, M., Savani, B. N., & Hamadani, M. (2021) · eJHaem · doi:10.1002/jha2.323 · Cited by 2
Carty, S. A., Murga‐Zamalloa, C., & Wilcox, R. A. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.04.007 · Cited by 2
Yao, Y., Yan, Y., Suman, V. J., Dietz, A. B., Erskine, C. L., Dimou, A., Markovic, S. N., McWilliams, R. R., Montane, H. N., & Block, M. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1491448 · Cited by 1
A novel TOX-nanoluciferase reporter mouse for exploring modulators of T cell exhaustion
Li, L. V., Mueller, Y. M., Hioki, K., den Dekker, R. J. H., Brouwers-Haspels, I., Mezzanotte, L., Maas, A., Erkeland, S. J., & Katsikis, P. D. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf009 · Cited by 1
Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia
Li, W., Lian, Y., Zhang, L., Li, R., Liang, Q., Mao, J., Qiu, C., Li, H., Huang, K., Li, Q., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04040-0 · Cited by 1
Yu, Y., Wang, W., Mo, Z., Fu, S., Wang, D., Teng, Y., Feng, J., Cui, J., Huang, S., Huang, H., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.010 · Cited by 1
Bhaimia, E., Russell, D., & Santos, C. A. Q. (2025) · ASM Case Reports · doi:10.1128/asmcr.00087-25 · Cited by 1
Rituximab-associated cryptococcal meningitis in systemic lupus erythematosus: A case report
Cadena, S., Bedón-Galarza, R., Cachumba, M., González-Andrade, F., & Baldeón, L. (2026) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2026.100762 · Cited by 1
Rao, A. K., Darwish, C. C., Campbell, K. S., Khanal, R., Fung, H., & Stack, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1727926 · Cited by 1
Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations
Escobar, G., & Maus, M. V. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201231 · Cited by 1
Chronic graft-versus-host disease
Ye, Y., Savani, B. N., Malard, F., Ruggeri, A., Aboudale, I., Perić, Z., Huang, H., & Mohty, M. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00711-z · Cited by 1
[Application of ibrutinib in primary central nervous system lymphoma].
Pang, D., Chen, F. L., & Li, W. Y. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.04.018 · Cited by 1
Clinical advances in immunotherapy for immune-mediated glomerular diseases
Tang, B., & Yang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01218-7 · Cited by 1
Ibrutinib and Neurolisteriosis: Simple Coincidence?
Dalmas, P., Mortier, C., Froidefond, M., Doudier, B., Dudouet, P., Collignon, A., Ebbo, M., Lagier, J., & Cassir, N. (2024) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.1280 · Cited by 1
Patagani, S., Balakrishna, K. J., Katari, N. K., Mahesh, P., & Gundla, R. (2024) · ChemistrySelect · doi:10.1002/slct.202402656 · Cited by 1
Chung, C., & Doan, D. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14408 · Cited by 1
The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma
Kuehn, J. C., Neidert, N. N., Zhang, J., Mutter, J., Alig, S., Klingler, C., Hummel, F., Ranganathan, L., Bleul, S., Beck, J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02600-y · Cited by 1
Boleto, G., Cauvet, A., Guignabert, C., Thuillet, R., Ottaviani, M., Tu, L., Hsu, L., Rosenbaum, J. T., Miller, R. A., & Allanore, Y. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03687-5 · Cited by 1
Wang, J., Cui, R., Qi, Y., Mu, J., Li, X., Li, Q., & Deng, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1674235 · Cited by 1
Ali, S. B., King, J. R., & Lucas, M. (2026) · International Archives of Allergy and Immunology · doi:10.1159/000550922 · Cited by 1
Ciosek, A., Hofmann, J., Galant, K., Marinkovich, M. P., Wierzbowska, A., Ciążyńska, M. A., Bień, N., Narbutt, J., & Lesiak, A. (2026) · Cells · doi:10.3390/cells15100874 · Cited by 1
Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies
Ni, Q., & Rui, L. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201281 · Cited by 1
Xing, X., Liu, H., Pang, Y., & Li, S. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108850 · Cited by 1
Song, P., Bai, G., Chan, S., Zhang, T., Tong, L., Su, Y., Shen, Y., Chen, Y., Liu, Y., Lai, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1071114 · Cited by 1
Novel Targets in Development for Advanced Renal Cell Carcinoma
Thapa, B., Nelson, A. A., & Kilari, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-40901-1_14 · Cited by 1
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Mei, M. G., Tsai, N., Palmer, J. M., Armenian, S. H., Chen, R., Rosen, S. T., Forman, S. J., Popplewell, L. L., Kwak, L. W., Martin, P., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.013 · Cited by 1
Self-citationGao, L., Wang, L., Wang, B., Wang, Q., Cen, X., & Dong, Y. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000547 · Cited by 1
Metadata
- Authors
- Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., & Byrd, J. C.
- Affiliations
- Department of Internal Medicine, Division of Hematology,
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- Weill Cornell Medicine (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Department of Pathology, and
- ORCID
- Beckwith, Kyle A.
- Natarajan, Gayathri
- Woyach, Jennifer A.
- Jaglowski, Samantha
- Chang, Betty Y.
- Chappell, Danielle L.
- Smith, Lisa L.
- Flynn, Joseph M.
- Jones, Jeffrey A.
- Andritsos, Leslie A.
- Maddocks, Kami
- Furman, Richard
- Sharman, Jeff
- Mishra, Anjali
- Caligiuri, Michael A.
- Satoskar, Abhay R.
- Muthusamy, Natarajan
- Johnson, Amy J.
- Byrd, John C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-10
- Volume
- 122
- Issue
- 15
- Pages
- 2539-2549
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3795457
- OpenAlex
- W2089103836
- Cited by
- 810
- References
- 49
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 55 · 2023: 51 · 2022: 70 · 2021: 98 · 2020: 68 · 2019: 71 · 2018: 71 · 2017: 70 · 2016: 65 · 2015: 67 · 2014: 43 · 2013: 5
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, P50CA140158, T32CA009338, 5 T32 CA009338-33-03, P30CA016058, K12CA133250, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- ibrutinib, irreversible kinase inhibitors, Bruton's tyrosine kinase, T cell signaling, Th1 response, Th2 immune response, chronic lymphocytic leukemia, Leishmania major, Listeria monocytogenes, immunomodulation
- MeSH terms
- Adenine, Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Leukemia, Listeriosis, Lymphocyte Activation, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leishmaniasis, Cutaneous, CD8-Positive T-Lymphocytes, Th1 Cells, Th2 Cells, Jurkat Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
